Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Raquel Celis, Alessandra Nerviani et al.|The Lancet|2021Cited by 315
Seronegative autoimmune diseases: A challenging diagnosisMarco Vincenzo Lenti, Antonio Di Sabatino, Matteo Gastaldi et al.|Autoimmunity Reviews|2022Cited by 87
Baseline Serum Concentrations of TRAIL in Early Rheumatoid Arthritis: Relationship with Response to Disease-modifying Antirheumatic DrugsPaola Secchiero, Francesco Trotta, Serena Bugatti et al.|The Journal of Rheumatology|2010Cited by 11